^
1d
Endothelial Transcription Factor EB Protects Against Doxorubicin-Induced Endothelial Toxicity and Cardiac Dysfunction. (PubMed, Circulation)
Taken together, endothelial TFEB protects against EC damage and cardiac dysfunction, constituting a potential target for treating cardiotoxicity induced by DOX. Our study provides new mechanistic insights into cardiotoxicity associated with chemotherapy.
Journal
|
TFEB (Transcription Factor EB 2)
|
doxorubicin hydrochloride
1d
LMNA-NTRK1-rearranged spindle cell neoplasm with multiple relapses: a case report and literature review. (PubMed, Front Med (Lausanne))
Through integrated histopathological, immunohistochemical, and molecular analyses, we characterize the diagnostic nuances, biological behavior, and potential drivers of progression in this entity. Our findings expand the morphological and clinical spectrum of LMNA::NTRK1-rearranged tumors and highlight the need for close follow-up and consideration of adjuvant targeted therapy in high-risk cases.
Journal
|
NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • LMNA (Lamin A/C) • NTRK (Neurotrophic receptor tyrosine kinase)
3d
A case report of retroperitoneal infantile fibrosarcoma with RBPMS-NTRK3 fusion gene positivity (PubMed, Zhongguo Dang Dai Er Ke Za Zhi)
Initial chemotherapy with the VAC regimen (vincristine, actinomycin D, and cyclophosphamide) was administered, but the response was poor. To our knowledge, this is the first reported case of infantile fibrosarcoma with RBPMS-NTRK3 fusion in China. Treatment with larotrectinib resulted in marked tumor shrinkage.
Journal
|
NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6) • RBPMS (RNA-binding protein with multiple splicing)
|
Vitrakvi (larotrectinib) • cyclophosphamide • vincristine • dactinomycin
3d
FDG PET/MRI and PET/CT Findings in a Case of Lung Metastases From Infantile Fibrosarcoma Harboring LMNA-NTRK1 Gene Fusion. (PubMed, Clin Nucl Med)
The lung metastases appeared as multiple nodules with irregular or smooth margins in both lungs and showed variable FDG uptake, ranging from low-grade to high-grade activity, which may reflect different biologic behavior of these tumors. The lung tumors disappeared or decreased significantly in size after tropomyosin receptor kinase inhibitor therapy.
Journal
|
NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • LMNA (Lamin A/C)
3d
Ursolic acid ameliorates ocular surface dysfunction in dry eye via targeting EGFR/RAS/RAF/MAP2K1/MAPK1 pathway. (PubMed, J Pharm Anal)
In vivo experiments confirmed the therapeutic efficacy of UA eye drops via the EGFR/RAS/RAF/MAP2K1/MAPK1 pathway. Collectively, these findings underscore the potential of UA eye drops as a promising therapeutic approach for managing ocular surface disorders in DE.
Journal
|
MAP2K1 (Mitogen-activated protein kinase kinase 1) • MAPK1 (Mitogen-activated protein kinase 1)
8d
Systemic STING agonist therapy drives expression of interferon stimulated genes and downstream production of cytokines in dogs with solid tumors. (PubMed, J Immunother Cancer)
These data identify tolerated dose levels for a novel, intravenously delivered STING agonist compound that results in on-target effects in systemic and intratumoral immune responses in dogs with solid tumors.
Journal
|
IL6 (Interleukin 6) • STING (stimulator of interferon response cGAMP interactor 1)
9d
Uterine Sarcomas Harbouring Novel FOXO1 Gene Rearrangements: Report of A Case Series. (PubMed, Am J Surg Pathol)
These cases expand the landscape of FOXO1-rearranged neoplasms and describe a potential new uterine mesenchymal entity. Further study of additional cases is needed to establish whether these rearrangements truly represent an initiating event for a distinct subset of uterine sarcomas, or whether FOXO1 rearrangements simply represent an additional noninitiating/nondriver event within other established tumor types.
Journal
|
MEIS1 (Meis Homeobox 1)
10d
CXCL10/CXCR3 axis facilitates the M2 polarization of macrophages in colorectal cancer via activating RAF. (PubMed, Discov Oncol)
Inhibitors of CXCR3 or RAF reversed these effects, confirming that CXCL10 promoted M2 polarization via the CXCR3/RAF/ERK pathway. Overall, the CXCL10/CXCR3 axis played a key role in CRC progression by inducing M2 polarization of macrophages via the RAF/ERK pathway, suggesting that CXCL10/CXCR3 axis may be a potential therapeutic target for CRC immunotherapy.
Journal • IO biomarker
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • IL10 (Interleukin 10) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • MRC1 (Mannose Receptor C-Type 1) • CD86 (CD86 Molecule)
11d
Beyond COL1A1::PDGFB: Rare fusions and their clinical implications in dermatofibrosarcoma protuberans. (PubMed, World J Clin Cases)
This fusion drives tumorigenesis and forms the basis for imatinib treatment, which acts by blocking platelet-derived growth factor receptor-beta kinase activity...In this editorial commentary, we briefly highlight the ever-growing genomic landscape of DFSP, report rare fusions and their biological implications, and examine the role of expanded molecular diagnostics in refining diagnosis, guiding therapy, and informing prognosis. Incorporating comprehensive fusion analysis into routine workup may be critical for accurate classification, especially in unusual presentations where reliance on morphology alone risks misdiagnosis.
Journal
|
PDGFRB (Platelet Derived Growth Factor Receptor Beta) • COL1A1 (Collagen Type I Alpha 1 Chain) • PDGFB (Platelet Derived Growth Factor Subunit B) • COL6A3 (Collagen Type VI Alpha 3 Chain)
|
imatinib
14d
Neoadjuvant TRK Inhibitors versus Chemotherapy in Advanced NTRK Fusion-Positive Sarcomas: A Real-World Evidence Analysis. (PubMed, Oncologist)
In children with NTRK fusion-positive sarcomas, upfront TRK inhibition yielded faster, deeper responses and eliminated mutilating surgery in our cohort. These data support TRK inhibitors as preferred neoadjuvant options, particularly to facilitate non-morbid resections and to avoid functional disability.
Journal • HEOR • Real-world evidence
|
NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK positive • NTRK fusion
16d
BRAF p.V600E Mutation in Mixed Odontogenic Tumors and Its Clinical Correlation: A Systematic Review and Meta-Analysis. (PubMed, Int Dent J)
Its presence in a substantial portion of AFO/AFD/DO, together with their larger size compared to OD, could support a neoplastic nature in at least a subset of these lesions, though a hamartomatous DO may exist. Further investigation and clinical correlation remain essential to distinguish these entities.
Retrospective data • Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
17d
ADVL1823: Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia (clinicaltrials.gov)
P2, N=33, Active, not recruiting, Children's Oncology Group | Trial completion date: Mar 2026 --> Jul 2027
Trial completion date
|
NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • ETV6 (ETS Variant Transcription Factor 6)
|
Vitrakvi (larotrectinib)